Progestin therapy is indicated for advanced or metastatic @entity1204 as well as a adjuvant therapy for primary @entity5 . There are several predictors of @entity5 responsiveness to the hormone. Sex @entity134 receptor(R) is a biochemical marker. Receptor analysis was done in 73 cases of primary @entity1204 . The concentrations of @entity172 (E), @entity1871 (P) and @entity342 (A) were found to correlate with the degree of @entity5 differentiation; well-differentiated @entity5 contains significantly greater receptors than moderately-and poorly-differentiated @entity5 . Both ER and PR were positive in about 80% of the well-differentiated @entity5 , but negative in 50% of the poorly-differentiated @entity5 . Analysis of 13 cases of @entity204 shows some correlation of the PR concentrations with the survival time. Receptor dynamics in @entity5 of the @entity1 enables us to predict possible site(s) of impaired responsiveness to progestin. Furthermore, in addition to progestin and @entity172 test, @entity440 challenge test is useful as in vivo sensitivity test. Moreover, receptor manipulation by @entity440 may be employed to enhance hormonal sensitivity of the @entity5 , particularly the low receptor one.

[Hormonal therapy of XXXX ].

@entity1204 :: ('MESH:D016889', 'Disease') :: ['endometrial cancer'] @entity172 :: ('MESH:D004967', 'Chemical') :: ['estrogen'] @entity1 :: ('9606', 'Species') :: ['patients'] @entity440 :: ('MESH:D013629', 'Chemical') :: ['tamoxifen'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'cancer', 'tumors'] @entity134 :: ('CHEBI:35341', 'Chemical') :: ['steroid'] @entity1871 :: ('CHEBI:59826', 'Chemical') :: ['progestin'] @entity342 :: ('CHEBI:50113', 'Chemical') :: ['androgen'] @entity204 :: ('MESH:D003643', 'Disease') :: ['death']
@entity1204 :: (MESH:D016889,Disease) :: ['endometrial cancer']
